Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models
FGF signaling plays a role in resistance to CDK4/6 inhibitors and ET in ER<sup>+</sup> BC. Tasurgratinib has the potential to exhibit significant antitumor activity in combination with ET against ER<sup>+</sup> BC via FGF signaling inhibition. These findings indicate the therapeutic potential of tasurgratinib in treating ER<sup>+</sup> BC.
Authors
- Kyoko Nishibata (ORCID: https://orcid.org/0000-0003-3153-0605)
- Ryu Gejima
- Saori Watanabe Miyano
- Sayo Fukushima (ORCID: https://orcid.org/0000-0003-1149-255X)
- Satoshi Kawano
Institutions
- Eisai (Japan) (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-24
- DOI
- https://doi.org/10.3390/cancers17071084
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00